Strategic Order of Osteoporosis Medications

Sequential therapy in osteoporosis requires precise mechanistic ordering because antiresorptives like bisphosphonates or denosumab blunt the bone-building efficacy of subsequent anabolic agents like teriparatide, abaloparatide, or romosozumab. Starting with an anabolic agent maximizes early bone mineral density gains and microarchitectural restoration by opening an uncoupling window. Conversely, transitioning from denosumab to an anabolic triggers a transient rebound in bone resorption, precipitating rapid bone loss and vertebral fracture risk if not blunted by a potent bisphosphonate bridge. Optimizing long-term skeletal strength necessitates initiating treatment with bone-forming agents first, followed immediately by antiresorptive consolidation to preserve accrued density.